CartiHeal

CartiHeal is a manufacturer of medical equipment that produces products for the restoration of articular cartilage and osteochondral defects.

History

2022: Bioventus bought CartiHeal for $450 million

On April 4, 2022, Bioventus announced the purchase of a private company for the production of medical equipment in the form of implants for the treatment of cartilage CartiHeal for $450 million. The transaction is expected to close in the second quarter of 2022 subject to certain normal closing conditions. Bioventus plans a limited release of CartiHeal products to the US market in the third quarter of 2022.

The Agili-C implant, which produces CartiHeal, is designed to treat grade III or higher knee surface damage according to the classification of the International Society for Cartilage Tissue Repair (ICRS), whose total area is 1-7 cm square meters. in patients without severe osteoarthritis, Kellgren-Lawrence score (KOOS) 0-3. The Agili-C implant is expected to be a cost-effective solution for cartilage regeneration and bone remodeling, designed to delay total knee replacement in patients with knee articular surface lesions. Agili-C represents an acellular finished implant for use in cartilaginous and osteochondral defects in traumatic and osteoarthrotic joints. implant is a porous, biocompatible and resorbable two-phase frame consisting of natural inorganic calcium carbonates connected to each other.

Bioventus bought CartiHeal for $450 million

The standard cell-free implant from CartiHeal has a European quality certificate for use in cartilage defects and bone-cartilage tissue. The devices are implanted in more than 500 patients with knee cartilage, ankle and thumb lesions during a series of clinical trials in leading centers in Europe and Israel to treat a wide range of cartilage lesions, from single focal lesions to multiple.

According to Bioventus CEO Ken Realia, CartiHeal represents an important breakthrough in the treatment of osteoarthritis, and Bioventus is pleased to add this additional product to the growing medical product portfolio. Realities added that the CartiHeal meets the need for joint preservation and cartilage regeneration for about 675 thousand American patients per year, which is a market opportunity for Bioventus in the amount of $1.3 billion, according to a press release.^[1]

Notes